Study Details

Cytomegalovirus (CMV) vaccine in donors and recipients undergoing allogeneic hematopoietic cell transplant (HCT)

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred). ID

The unique identification code given to each clinical study upon registration at

Astellas Study ID

The unique identification code given by the study sponsor.


EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).



Leukemia - AML, Leukemia - CML, Lymphoma, Bone Marrow Cancer


These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2


18 Years - 65 Years


Female & Male




A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


Trial Dates

Jan 2006 - Nov 2010


Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Enrollment number


A Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity, and Clinical Benefit of a CMV Immunotherapeutic Vaccine in Donors and CMV-Seropositive Recipients Undergoing Allogeneic, Matched Hematopoietic Cell Transplant (HCT)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Cytomegalovirus (CMV) vaccine in donors and recipients undergoing allogeneic hematopoietic cell transplant (HCT)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.


Mayo Clinic

Rochester, United States, 55905

Memorial Sloan Kettering Cancer Center

New York, United States, 10021

Montefiore Medical Center

Bronx, United States, 10467

University of Chicago

Chicago, United States, 60637

Baylor University Medical Center

Dallas, United States, 75246

City of Hope National Medical Center

Duarte, United States, 91010

Arizona Cancer Center

Tucson, United States, 85724

Karmanos Cancer Institute

Detroit, United States, 48201

Strong Memorial Hospital

Rochester, United States, 14642

Fred Hutchinson Cancer Research Center

Seattle, United States, 98109-1024

University of South Florida

Tampa, United States, 33612

Hackensack University Medical Center # 408

Hackensack, United States, 07601

Rocky Mountain Cancer Center

Denver, United States, 80218

University of Nebraska Medical Center

Omaha, United States, 68198

Emory University

Atlanta, United States, 30322

North Carolina Baptist Hosptial

Winston-Salem, United States, 27157

James Graham Brown Cancer Center

Louisville, United States, 40202

University of Kansas Medical Center

Westwood, United States, 66205

Brigham and Women's Hospital

Boston, United States, 02115

Rush University Medical Center

Chicago, United States, 60612

University of Texas Southwestern Medical Center at Dallas

Dallas, United States, 75390

Roswell Park Cancer Institute Corporation

Buffalo, United States, 14263